ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

PYC Physiomics Plc

1.55
0.20 (14.81%)
Last Updated: 10:24:35
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Physiomics Plc LSE:PYC London Ordinary Share GB00BDR6W943 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.20 14.81% 1.55 1.50 1.60 1.60 1.35 1.35 1,778,188 10:24:35
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 597k -477k -0.0035 -4.43 2.1M

Physiomics PLC Two New Pre-Clinical Contracts (4987M)

31/07/2017 7:00am

UK Regulatory


Physiomics (LSE:PYC)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Physiomics Charts.

TIDMPYC

RNS Number : 4987M

Physiomics PLC

31 July 2017

Physiomics plc

("Physiomics") or ("the Company")

Two new pre-clinical contracts

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today signed two new contracts with a global pharma company for Virtual Tumour pre-clinical predictions relating to a new oncology target. This marks the sixth year of collaboration with this company since a first pre-clinical project was announced in March 2012.

The two contracts will be executed in parallel between now and the end of the calendar year.

Jim Millen, CEO said: "We are delighted by these new contracts which we believe are a sign of the client's long-term commitment to Physiomics and its Virtual Tumour technology. We look forward to continuing to work closely with them going forwards".

This announcement refers to a contract in the ordinary course of business for Physiomics.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

WH Ireland Limited (nomad)

Katy Mitchell

+44 (0) 161 832 2174

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

This information is provided by RNS

The company news service from the London Stock Exchange

END

CNTLLFVRDEITFID

(END) Dow Jones Newswires

July 31, 2017 02:00 ET (06:00 GMT)

1 Year Physiomics Chart

1 Year Physiomics Chart

1 Month Physiomics Chart

1 Month Physiomics Chart

Your Recent History

Delayed Upgrade Clock